| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -3.1 | -7.5 |
| Net income | -3.1 | -7.5 |
| EPS (diluted, $ a share) | $-2.51 | $-29.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AMIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Autonomix Medical, Inc.: key numbers
- Share price
- $1.08Close, Nov 17
- Market cap
- $2.21M
- Shares outstanding
- 2.05MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Autonomix Medical, Inc.
All →Autonomix Medical Shareholder Meeting
Autonomix Medical held its 2026 Annual Meeting of Stockholders on October 29, 2026, where shareholders elected six directors and ratified Forvis Mazars, LLP as the independent auditor. Stockholders also approved an amendment to the 2023 Stock Plan to increase authorized shares by 750,000 and granted the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25.
Autonomix Medical Leadership Change
Autonomix Medical has appointed Sandra Kalter, the former Chief Regulatory Counsel and Vice President of Medtronic, to its Board of Directors, increasing the board size from five to six members. Ms. Kalter brings over 40 years of MedTech experience, including regulatory strategy and M&A due diligence for major medical device platforms. She will participate in the company's standard compensation program for non-employee directors.
- Counterparty
- Sandra Kalter